Top Markets
Coin of the day
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rank in Stocks #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Share Price
$0.2483
Last synced: 2026-07-31
Market Cap
$2.30M
Change (1 day)
-3.39%
Change (1 year)
-89.01%
Country
US
Trade Ensysce Biosciences, Inc. (ENSC)

Category

P/E ratio for Ensysce Biosciences, Inc. (ENSC)
P/E ratio as of September 2026 TTM: -0.17
According to Ensysce Biosciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.17. At the end of 2023 the company had a P/E ratio of -3.39.
P/E ratio history for Ensysce Biosciences, Inc. from 2017 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.17 -90.20%
2024 -1.78 -47.51%
2023 -3.39 237.53%
2022 -1.00 -97.94%
2021 -48.88 -100.00%
2020 3.52M 463.02%
2019 624.36K -494.92%
2018 -158.10K -97.60%
2017 -6.60M 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
29.99 -17,298.85%
US
-18.38 10,440.25%
US
36.30 -20,911.58%
NL
-23.34 13,281.42%
AU
- -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.